Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2020
[A study of alexithymia in schizophrenia and some somatic diseases].
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kafarov T A, Aliev N A, Aliyev Z N
Аннотация
OBJECTIVE: To study alexithymia in schizophrenia and some somatic diseases.
MATERIAL AND METHODS: The study included 60 patients with paranoid schizophrenia (ICD-10 F20.0), 55 hypertensive patients with primary heart disease (I11), 53 patients with chronic ischemic heart disease (I25) and 51 patients with insulin-dependent diabetes mellitus (E10). To assess the manifestations of alexithymia, the Toronto alexithymia scale (TAS-26) was used. The Positive and negative syndrome scale (PANSS) was administered to patients with schizophrenia.
RESULTS: The average scores on TAS were higher in patients with schizophrenia compared to patients with somatic diseases (109,73 and 81,66, respectively). During the analysis of responses to TAS statements, features of a general and particular nature were identified.
CONCLUSIONS: Alexithymia is not a property characteristic of psychosomatic diseases and neurotic disorders, and is detected in schizophrenic patients and patients with somatic diseases. The relationship of alexithymia with negative symptoms of schizophrenia suggests that it might impact on interpersonal relations, social adaptation and development of autistic symptoms in patients.
MATERIAL AND METHODS: The study included 60 patients with paranoid schizophrenia (ICD-10 F20.0), 55 hypertensive patients with primary heart disease (I11), 53 patients with chronic ischemic heart disease (I25) and 51 patients with insulin-dependent diabetes mellitus (E10). To assess the manifestations of alexithymia, the Toronto alexithymia scale (TAS-26) was used. The Positive and negative syndrome scale (PANSS) was administered to patients with schizophrenia.
RESULTS: The average scores on TAS were higher in patients with schizophrenia compared to patients with somatic diseases (109,73 and 81,66, respectively). During the analysis of responses to TAS statements, features of a general and particular nature were identified.
CONCLUSIONS: Alexithymia is not a property characteristic of psychosomatic diseases and neurotic disorders, and is detected in schizophrenic patients and patients with somatic diseases. The relationship of alexithymia with negative symptoms of schizophrenia suggests that it might impact on interpersonal relations, social adaptation and development of autistic symptoms in patients.